Never unvaccinated controls
[back] Medical study ploys

[There has never been (that anyone has found) any vaccine study done using 100% unvaccinated children as controls.  They know it would show up their vaccine to be unsafe and/or useless, and that Unvaccinated children are healthier as Dan Olmsted found in the Amish.  The cover story: it would be unethical to leave a control group of children unprotected against vaccine-preventable disease (Orac quote).  There are tens of thousands of unvaccinated kids around to study.]

See: Healthy trial babies only  Inadequate safety studies  Leicester

See: DPT Mouse tests Mouse toxicity test  Kendrick mouse test  Hist test

[Swine flu vax 2009 Aug] Injecting one thing for testing and then adding adjuvant later

[2007] SEEKING THE TRUTH ABOUT THE NEVER-VACCINATED by Sandy Gottstein

[2009 Feb] Unvaccinated Children Madness By J.B. Handley  One final point: the mainstream will never do a study of unvaccinated kids. They already fear what it will show, and the results for them would likely be cataclysmic. Their best bet is to invent reasons the study can't be done.

Quotes
"One of the flaws in studies of vaccines is that there are no true placebo groups. The vaccine is tested in one group of immunized children and is compared to another group of immunized children."--Peter Baratosy

Allowing other than sterile saline to be used as the placebo in short-term vaccine adverse-reaction studies to suppress the relative incidence rates to the point that these relative adverse-event rates show “no statistically significant” increase over the “placebo” (that, in some cases, has been allowed to be an experimental vaccine or the vaccine formulation without the biological antigens).
    Permitting vaccine safety studies to be restricted to a few days or, at most, a few of months even though some severe adverse outcomes do not begin to emerge until several years after vaccination (e.g., childhood MS 4 years after vaccination).
    Consenting to reductions in the size and number of persons in the phase-III clinical trials that not only reduce the vaccine makers costs but also reduce the risk that the study will find the rare but deadly adverse effects that a vaccine may have.
    Allowing surrogate endpoints (e.g., the reactivity of the patient’s blood to animal anti-sera) for specific antibodies to be used to assess vaccine efficacy instead of requiring comprehensive testing to establish both general and specific immunity in those vaccinated that is comparable to the immunity found in those who have had the disease.
    Recommending widespread use of new vaccines long before the long-term (at least 10-year) outcomes can be assessed in the trial population, and
    Licensing vaccines and recommending their “universal” use in populations that have near-zero risk of contracting a disease (e.g., the hepatitis B vaccine in young children or the HPV vaccine in non-sexually-active children) or where the clinical cases of the disease occur at low rate and are virtually absent in most demographic segments of U.S. population (e.g., the rotavirus vaccine). Key realities about autism, vaccines, vaccine-injury compensation, Thimerosal, and autism-related research----Gary S. Goldman, Ph.D & P.G. King PhD